A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis (NCT03958877)
An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric participants with RRMS in Part 1. In Part 2, the study will evaluate the long-term safety of BIIB017 and further describe safety and the long-term multiple sclerosis (MS) outcomes after BIIB017 treatment in participants who completed the study treatment at Week 96 in Part 1 of the study.
Who can join: Review the eligibility criteria below.
Location: UC San Diego Health — La Jolla, California
Age range: 10 Years to 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (65 Sites)
Showing the first 25 of 65 sites.
- UC San Diego Health — La Jolla, California
- UNC Hospitals — Chapel Hill, North Carolina
- Meridian Clinical Research — Norfolk, Virginia
- Hospital Italiano de Buenos Aires — Ciudad Autonoma Buenos Aires, Buenos Aires
- Royal Children's Hospital — Parkville, Victoria
- Universitair Ziekenhuis Ghent — Ghent, East Flanders
- Clinique CHC MontLégia — Liège, Wallonia
- MHATNP 'Sv.Naum', EAD — Sofia,
- University Hospital Centre Split — Split, Dalmatia
- Children's Hospital Zagreb — Zagreb,
- Clinical Hospital Center 'Sestre Milosrdnice' — Zagreb,
- University Hospital Centre Zagreb — Zagreb,
- Fakultni nemocnice Hradec Kralove — Hradec Králové,
- CHU Strasbourg - Hôpital Hautepierre — Strasbourg, Bas Rhin
- Hopital Purpan — Toulouse, Haute Garonne
- Hopital Gui de Chauliac — Montpellier, Herault
- Hopital Roger Salengro - CHU Lille — Lille, Nord
- Hôpital Bicêtre — Le Kremlin-Bicêtre, Val De Marne
- Universitaetsklinikum Freiburg — Freiburg im Breisgau, Baden-Wurttemberg
- Universitaetsmedizin Goettingen — Göttingen, Lower Saxony
- St. Josef-Hospital Universitaetsklinikum — Bochum, North Rhine-Westphalia
- Charité - Campus Virchow-Klinikum — Berlin,
- General Hospital of Larissa — Larissa, Thessaly
- General Hospital of Thessaloniki 'Hippokration' — Thessaloniki,
- Pecsi Tudomanyegyetem KK — Pécs, Baranya
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Sclerosis, Relapsing-Remitting
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS — Aurora, Colorado
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial — Birmingham, Alabama
- Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis — Altamonte Springs, Florida
- A Post-Authorization, Long-term Study of Ozanimod Real-world Safety — Bethesda, Maryland
- Efficacy of Diet on Quality of Life in Multiple Sclerosis — Iowa City, Iowa
Explore by condition: All Multiple Sclerosis, Relapsing-Remitting clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.